https://t.co/wPUeoJ6Co2 #teplizumab less loss of C-peptide, in drug-treated responders identified at 1 year. However, the improvements in C-peptide response were not associated with lower HbA1c levels or insulin use. https://t.co/B226o0WjzP
@DeanSorenmann @zoehaswitt @mythigator @Jezebel I'm wondering if a follow up series can be done after the efficacy wears off. The study I ran across was a seven year published in 2019. (https://t.co/7U10Kgv2Wl ). Two weeks of injections every 7-8 years wou
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. https://t.co/qsVPjm7TLo
@John_LaMattina - Good article in @Forbes about Teplizumab. A recent article showed safety at 7 years post treatment (https://t.co/dPqHfqeAZF). You also mentioned that Provention Bio was part of the recent study - the company was not part of the study but
RT @profsmarshall: Up front & free to read in April's @DiabetologiaJnl: Long-term follow-up of teplizumab in type 1 diabetes shows sustaine…
RT @profsmarshall: Up front & free to read in April's @DiabetologiaJnl: Long-term follow-up of teplizumab in type 1 diabetes shows sustaine…
RT @profsmarshall: Up front & free to read in April's @DiabetologiaJnl: Long-term follow-up of teplizumab in type 1 diabetes shows sustaine…
RT @profsmarshall: Up front & free to read in April's @DiabetologiaJnl: Long-term follow-up of teplizumab in type 1 diabetes shows sustaine…
RT @profsmarshall: Up front & free to read in April's @DiabetologiaJnl: Long-term follow-up of teplizumab in type 1 diabetes shows sustaine…
RT @profsmarshall: Up front & free to read in April's @DiabetologiaJnl: Long-term follow-up of teplizumab in type 1 diabetes shows sustaine…
RT @profsmarshall: Up front & free to read in April's @DiabetologiaJnl: Long-term follow-up of teplizumab in type 1 diabetes shows sustaine…
RT @profsmarshall: Up front & free to read in April's @DiabetologiaJnl: Long-term follow-up of teplizumab in type 1 diabetes shows sustaine…
RT @profsmarshall: Up front & free to read in April's @DiabetologiaJnl: Long-term follow-up of teplizumab in type 1 diabetes shows sustaine…
RT @profsmarshall: Up front & free to read in April's @DiabetologiaJnl: Long-term follow-up of teplizumab in type 1 diabetes shows sustaine…
RT @profsmarshall: Up front & free to read in April's @DiabetologiaJnl: Long-term follow-up of teplizumab in type 1 diabetes shows sustaine…
Up front & free to read in April's @DiabetologiaJnl: Long-term follow-up of teplizumab in type 1 diabetes shows sustained C-peptide & immunological responses in drug-treated responders 7 yrs after diagnosis @YaleIBIO @YaleMed #type1diabetes #Immuno
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis https://t.co/SDcFmQmuo0
RT @DiabetologiaJnl: Long-term follow-up of teplizumab in type 1 diabetes shows sustained C-peptide and immunological responses in drug-tre…
RT @DiabetologiaJnl: Long-term follow-up of teplizumab in type 1 diabetes shows sustained C-peptide and immunological responses in drug-tre…
RT @DiabetologiaJnl: Long-term follow-up of teplizumab in type 1 diabetes shows sustained C-peptide and immunological responses in drug-tre…
RT @DiabetologiaJnl: Long-term follow-up of teplizumab in type 1 diabetes shows sustained C-peptide and immunological responses in drug-tre…
RT @DiabetologiaJnl: Long-term follow-up of teplizumab in type 1 diabetes shows sustained C-peptide and immunological responses in drug-tre…
RT @DiabetologiaJnl: Long-term follow-up of teplizumab in type 1 diabetes shows sustained C-peptide and immunological responses in drug-tre…
RT @DiabetologiaJnl: Long-term follow-up of teplizumab in type 1 diabetes shows sustained C-peptide and immunological responses in drug-tre…
Long-term follow-up of teplizumab in type 1 diabetes shows sustained C-peptide and immunological responses in drug-treated responders 7 years after diagnosis @YaleIBIO @YaleMed #type1diabetes #immunotherapy https://t.co/ogVK9AUy0K #toptweet https://t.co/B8
RT @DiabetologiaJnl: Long-term follow-up of teplizumab in type 1 diabetes shows sustained C-peptide and immunological responses in drug-tre…
Long-term follow-up of teplizumab in type 1 diabetes shows sustained C-peptide and immunological responses in drug-treated responders 7 years after diagnosis @YaleIBIO @YaleMed #type1diabetes #immunotherapy https://t.co/ogVK9ACX9c https://t.co/FmKT4xtmwb